Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-07-13 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
关于增选公司独立非执行董事候选人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the nomination and election of an independent non-executive director candidate for the company 百奥泰生物制药股份有限公司. It includes details about the candidate's qualifications, background, and the board's approval process. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings release, and no regulatory filings related to financial performance. The content clearly relates to changes or additions in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on this specific board change, confirming the classification.
2020-07-13 Chinese
关于购买董监高责任保险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 百奥泰生物制药股份有限公司 regarding the purchase of directors and officers liability insurance. It details the insurance coverage, insured parties, limits, premiums, and authorization for the board to handle related matters. It also mentions that the matter will be submitted to the shareholders' meeting for approval. There is no financial data, no report attached or referenced as published, and no indication of a full report or regulatory filing. This is a corporate announcement about management-related insurance coverage, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Board/Management Information (MANG) which is for changes in board or management, or Capital/Financing Update (CAP) which is for financing activities. Therefore, the classification is RNS with high confidence.
2020-07-13 Chinese
第一届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 17th meeting of the first board of directors of 百奥泰生物制药股份有限公司. It includes multiple agenda items such as approval of reports, amendments to company bylaws and governance documents, appointment of directors, appointment and change of auditors, insurance for directors and officers, and proposals for shareholder meetings. The document contains voting results for each resolution and references to further shareholder approval. The content focuses on board decisions, governance rules, and management appointments rather than financial results or audit reports themselves. It is not a full annual report, audit report, or earnings release. It is not a call transcript or investor presentation. The document is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length (over 11,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is MANG with high confidence.
2020-07-13 Chinese
关于贝伐珠单抗注射液（BAT1706）上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a drug marketing authorization application by the National Medical Products Administration (NMPA) in China. It details the receipt of an official acceptance notice for the drug BAT1706, including regulatory approval status and risk disclosures. The document is short (1233 characters) and serves as a formal announcement of a regulatory milestone rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory announcement category, as it informs investors and the public about a regulatory approval process event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-06-19 Chinese
关于公司筹划发行H股股票并在香港上市相关事项的提示性的更正公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement correcting a previous disclosure about the company's stock code related to its planned H-share issuance and Hong Kong listing. It does not contain financial statements, detailed financial data, or comprehensive report content. It is a correction notice related to a capital market activity (stock issuance and listing). Given the nature of the announcement about stock issuance and listing, and the correction of a previous announcement, the most appropriate classification is Capital/Financing Update (CAP). The document length is very short and it is not a full report or regulatory filing. Confidence is high due to clear context and content.
2020-06-16 Chinese
关于公司筹划发行H股股票并在香港上市相关事项的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (774 characters) regarding the company's plan to issue H shares and list on the Hong Kong Stock Exchange. It mentions board meeting resolutions and ongoing discussions but does not contain financial statements or detailed financial data. It also states that the matter is subject to approvals and has significant uncertainty. The document serves as a preliminary notice or update about a potential capital raising and listing event, rather than the actual issuance or detailed financing terms. Therefore, it fits best under Capital/Financing Update (CAP).
2020-06-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.